229 related articles for article (PubMed ID: 26415543)
1. Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug.
Gwenin VV; Poornima P; Halliwell J; Ball P; Robinson G; Gwenin CD
Biochem Pharmacol; 2015 Dec; 98(3):392-402. PubMed ID: 26415543
[TBL] [Abstract][Full Text] [Related]
2. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation.
Emptage CD; Knox RJ; Danson MJ; Hough DW
Biochem Pharmacol; 2009 Jan; 77(1):21-9. PubMed ID: 18840409
[TBL] [Abstract][Full Text] [Related]
3. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
4. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
5. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.
Race PR; Lovering AL; White SA; Grove JI; Searle PF; Wrighton CW; Hyde EI
J Mol Biol; 2007 Apr; 368(2):481-92. PubMed ID: 17350040
[TBL] [Abstract][Full Text] [Related]
6. Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954.
Anlezark GM; Vaughan T; Fashola-Stone E; Paul Michael N; Murdoch H; Sims MA; Stubbs S; Wigley S; Minton NP
Microbiology (Reading); 2002 Jan; 148(Pt 1):297-306. PubMed ID: 11782522
[TBL] [Abstract][Full Text] [Related]
7. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
8. Time dependent HPLC analysis of the product ratio of enzymatically reduced prodrug CB1954 by a modified and immobilised nitroreductase.
Ball P; Thompson E; Anderson S; Gwenin V; Gwenin C
Eur J Pharm Sci; 2019 Jan; 127():217-224. PubMed ID: 30414836
[TBL] [Abstract][Full Text] [Related]
9. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
[TBL] [Abstract][Full Text] [Related]
10. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
Drabek D; Guy J; Craig R; Grosveld F
Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
[TBL] [Abstract][Full Text] [Related]
11. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.
Knox RJ; Friedlos F; Sherwood RF; Melton RG; Anlezark GM
Biochem Pharmacol; 1992 Dec; 44(12):2297-301. PubMed ID: 1472095
[TBL] [Abstract][Full Text] [Related]
12. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).
Anlezark GM; Melton RG; Sherwood RF; Coles B; Friedlos F; Knox RJ
Biochem Pharmacol; 1992 Dec; 44(12):2289-95. PubMed ID: 1472094
[TBL] [Abstract][Full Text] [Related]
13. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ
Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510
[TBL] [Abstract][Full Text] [Related]
14. An unusually cold active nitroreductase for prodrug activations.
Çelik A; Yetiş G
Bioorg Med Chem; 2012 Jun; 20(11):3540-50. PubMed ID: 22546205
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
[TBL] [Abstract][Full Text] [Related]
16. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
17. uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.
Prosser GA; Patterson AV; Ackerley DF
J Biotechnol; 2010 Oct; 150(1):190-4. PubMed ID: 20727918
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of CB1954 reduction by Escherichia coli nitroreductase.
Christofferson A; Wilkie J
Biochem Soc Trans; 2009 Apr; 37(Pt 2):413-8. PubMed ID: 19290872
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
20. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
